Alzheimer’s Patients Could Die From Risperdal: Study

Law360, New York (January 9, 2009, 12:00 AM EST) -- A new study has found that Alzheimer’s disease patients who take anti-psychotic drugs such as Johnson & Johnson's Risperdal may face a doubled risk of death, further bolstering concerns over a possible correlation between such medications and a higher death rate in individuals with dementia.

The study, published Friday in the medical journal Lancet, found an increased long-term risk of mortality in patients with Alzheimer's who are prescribed anti-psychotic medication.

“Estimates of mortality for the whole study period showed a significantly increased risk of mortality for...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.